Modern NET trials with Quantitative SSTR PET, Dosimetry, and Harmonized Central Imaging
Neuroendocrine tumors (NETs) arise in the gastroenteropancreatic system, lungs, and other sites, often at advanced stages. NETs are classified by differentiation, Ki-67, and mitotic rate, informing prognosis and therapy. A hallmark is somatostatin receptor (SSTR) expression, enabling somatostatin analogues (SSAs) to control hormone secretion and tumor growth. Higher SSTR expression correlates with improved outcomes, and emerging strategies such as epigenetic modulation and SSA–mTOR combinations aim to optimize disease control. In clinical trials, imaging is critical for patient selection and response assessment, aligning endpoints with mechanism-driven therapies.
Building on these insights, the therapeutic landscape for NETs has expanded. Peptide receptor radionuclide therapy (PRRT) with ¹⁷⁷Lu-DOTATATE improves outcomes in SSTR-positive disease, while targeted agents (everolimus, sunitinib) benefit pancreatic NETs. The intrinsic gamma emission of ¹⁷⁷Lu enables SPECT/CT dosimetry to quantify absorbed dose for tumors and organs, refining precision. Industry trends emphasize harmonized acquisition, centralized reads, and quantitative dosimetry to generate regulatory-grade evidence, with growing use of ⁶⁸Ga- and ⁶⁴Cu-labeled tracers and site qualification to ensure data integrity.
⁶⁸Ga-DOTATATE PET/CT is the gold standard for functional imaging in NETs, with superior sensitivity and specificity versus conventional imaging. In trials of well-differentiated NETs, progression-free survival remains the primary endpoint, while imaging-based secondary and exploratory endpoints add complementary insight. These include optimized RECIST 1.1 response assessments, modified or volumetric criteria (e.g., mRECIST, Choi), SSTR PET uptake metrics, lesion-specific absorbed dose, and quantitative PET parameters such as SUV, tumor-to-liver ratio, and total lesion SSTR expression. While RECIST 1.1 is the FDA-recognized standard, SSTR PET/CT and functional metrics are increasingly integrated as exploratory endpoints, providing functional, volumetric, and dosimetry information.
Advances in NET management are driven by precision medicine focused on overcoming resistance, refining patient selection, and monitoring tumor evolution in real time. Strategies include epigenetic modulation to restore SSTR expression, combinations pairing PRRT with immunotherapy or DNA damage repair inhibitors, and novel alpha-emitting radioligands such as ²¹²Pb-DOTATATE and ²²⁵Ac-DOTATATE. Targeted alpha therapies are gaining prominence, with ²²⁵Ac, ²¹²Pb, and other SSTR-targeted compounds showing promising efficacy. Emerging theranostic pairs, including ⁶⁴Cu/⁶⁷Cu and ²⁰³Pb/²¹²Pb, further enable precision imaging and individualized treatment.
At Imaging Endpoints, advanced imaging is redefining NET trials, integrating rigorous standard criteria with SSTR PET and dosimetry solutions for validated, submission-ready imaging review.
IE is at the forefront with a flawless inspection record, and 95% marketing authorization success rate across over 200 regulatory approvals – reflecting strategic imaging science with integrated quality by design.
Reach out to us to connect with our experienced medical and scientific experts and explore how our tailored imaging solutions can support your NET clinical trials. For more information,
